Pharma major Lupin Limited has launched the world’s first fixed-dose triple combination drug (FDC) under the Vilfuro-G brand for the treatment of chronic obstructive pulmonary disease (COPD) in India.
This milestone follows an approval granted by the Drug Controller General of India for the dry powder inhaler (DPI) product.
Shares of the company are, however, trading 2.04 percent down at Rs 1193.80 at 10.50am on the NSE as most companies in the industry are trading lower on the indices.
Lupin Vilfuro-G is the only FDC that combines vilanterol, fluticasone furoate and glycopyrronium bromide, for the long-term management and treatment of moderate to severe COPD, the company said in a press statement on November 23.
The product will be available in a single-strength fixed dose, with a recommended once-daily dosage.
India has more than 37 million individuals struggling with COPD. It is a condition that ranks among the leading causes of death and disability in the nation.
“This milestone reinforces our resolve to expanding our respiratory portfolio providing COPD patients with the access to healthcare solutions, and transforming lives,” said Nilesh Gupta, managing director of Lupin, in a press statement.
Earlier, Lupin Ltd had reported a 3.77-fold year-on-year rise in consolidated net profit to Rs 489.6 crore for the July-September quarter of the current financial year. Revenue came in at Rs 5038.56 crore, up 24.9 percent from the year-ago quarter numbers of Rs 4145.5 crore.
Also read: Lupin Q2 results: Net Profit rises 3.77 times to Rs 489.6 crore, North America sales up 40% YoY
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
